HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Vogl, T. J. Articles by Nour-Eldin, N.-E. A. PubMed PubMed Citation Articles by Vogl, T. J. Articles by Nour-Eldin, N.-E. A. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols

¹ All authors: Institute for Diagnostic and Interventional Radiology, Johan Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, Hessen 60590, Germany.

OBJECTIVE. The objective of our study was to retrospectively determine the effectiveness of hepatic transarterial chemotherapy using two therapeutic protocols—mitomycin C alone and combined mitomycin C and gemcitabine—on local tumor control and survival rate in patients with liver metastases from neuroendocrine tumors.

MATERIALS AND METHODS. This article describes a retrospective study of 48 patients (age range, 37–77 years; mean age, 61.1 years; SD, 10.3) with liver metastases from neuroendocrine tumors who underwent repetitive selective hepatic artery chemotherapy using mitomycin C alone (group 1, n = 18 patients who underwent 182 therapeutic sessions; mean, 10.11 sessions per patient) and combined mitomycin C and gemcitabine chemotherapy agents (group 2, n = 30 patients who underwent 312 therapeutic sessions; mean, 10.4 sessions per patient) with 4-week intervals between treatment sessions.

RESULTS. Both treatment protocols were well tolerated by all patients. Only minor side effects occurred in both groups, and no major complications developed. Local tumor control evaluation according to the Response Evaluation Criteria in Solid Tumors (RECIST) revealed the following for group 1: partial response, 11.1%; stable disease, 50%; and progressive disease, 38.9%. RECIST criteria for group 2 indicated partial response in 23.33%, stable disease in 53.34%, and progressive disease in 23.33%. The survival rate from the initial diagnosis to the fifth year for group 1 was 11.11% and for group 2, 46.67%. The median survival time from the initial diagnosis of group 1 was 38.67 months, whereas in group 2 it was 57.1 months.

CONCLUSION. Transarterial hepatic chemotherapy using mitomycin C and gemcitabine can be an effective therapeutic protocol for controlling local metastases and improving survival time in patients with hepatic metastases from neuroendocrine tumors.

Keywords: liver metastases • neuroendocrine tumors • oncologic imaging • transarterial chemotherapy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?